Price T Rowe Associates Inc Aquestive Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 42,942 shares of AQST stock, worth $249,063. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,942
Previous 32,094
33.8%
Holding current value
$249,063
Previous $94,000
52.13%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding AQST
# of Institutions
125Shares Held
47.4MCall Options Held
64.2KPut Options Held
204K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$56.9 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$31.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$25.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$17.3 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.19MShares$12.7 Million0.32% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $309M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...